Skip to content

UC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study

The UC Davis Cohort of Pre-Malignant and Malignant GastroIntestinal DisEases (TUMMIE) Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05021029
Acronym
TUMMIE
Enrollment
1000
Registered
2021-08-25
Start date
2021-07-13
Completion date
2030-10-31
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Gastritis, Autoimmune Gastritis, Chronic Gastritis, Gastric Polyps, Intestinal Dysplasia, Intestinal Metaplasia

Brief summary

The UC Davis Cohort of Pre-Malignant and Malignant GastroIntestinal DisEases (TUMMIE) Study is a prospective longitudinal cohort study designed to improve understanding of the natural history, risk factors, and biological mechanisms underlying gastric pre-malignant conditions and progression to gastric cancer. The study will enroll up to 1,000 adults diagnosed with chronic gastritis, atrophic gastritis, autoimmune gastritis, gastric intestinal metaplasia, gastric dysplasia, or gastric polyps and follow participants for at least five years.

Detailed description

The TUMMIE Study will establish a prospective cohort of adults receiving care within the UC Davis Health System who have been diagnosed with gastric pre-malignant conditions. Participants will be identified through electronic health records, healthcare provider referrals, and StudyPages recruitment. Enrolled participants will complete baseline and annual follow-up assessments and may consent to collection of clinical data and biospecimens. The study aims to: Establish a prospective cohort of individuals with gastric pre-malignant conditions to monitor neoplastic progression. Identify host, tissue, and microbiome biomarkers associated with disease initiation and progression. Characterize the natural history of gastric pre-malignant lesions. Evaluate lifestyle, behavioral, environmental, and social determinants of health associated with gastric cancer risk. Clinical information will be obtained through electronic medical record review, including pathology findings, diagnosis dates, treatments, endoscopic procedures, and relevant risk factors. Biospecimens will be analyzed using multi-omics technologies, including DNA sequencing, RNA sequencing, proteomics, metabolomics, and metagenomic profiling. Helicobacter pylori screening will also be performed as part of the research program. By integrating longitudinal clinical data, epidemiologic information, and molecular profiling, this study seeks to improve risk stratification and inform future prevention, surveillance, and early detection strategies for gastric cancer.

Interventions

None listed

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. UCDHS patients 2. Of all races/ethnicities 3. Diagnosed with premalignant conditions such as chronic gastritis, atrophic gastritis, autoimmune gastritis, gastric intestinal metaplasia, gastric intestinal dysplasia or gastic polyps 4. During the last 5 years and current years to come (2015-2030) 5. Some participants may be scheduled for endoscopy

Exclusion criteria

* We will not include children (anyone under the age of 18), individuals unable to consent, pregnant women, or prisoners.

Design outcomes

Primary

MeasureTime frameDescription
Pre-malignant progressionBaseline, and yearly for 5 years.Review the number of patients with gastric conditions and any progression to advanced pre-neoplasia/malignancy or cancer and identify and characterize host and microbiome biomarkers associated with initiation and progression of gastric pre-malignancies

Secondary

MeasureTime frameDescription
Recruitment response ratesBaseline and yearly for 5 yearsReview number of patients response rates who donated full/partial biospecimen samples.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLuis G Carvajal-Carmona, PhD

University of California, Davis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026